AzTrials
AzTrials

SARS-CoV-2Phase 2SARS-CoV-2NCT06489860

SARS-CoV-2 Safety Study for the Treatment of COVID-19

A Phase 2 study testing HIV and Malignant Neoplasms Safety Study for the Treatment of Neoplasms in people with SARS-CoV-2, run by DHA Coffee Co., Ltd.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules. Read more about this study

Who is it for?
Ages 1 year to 130 yearsHealthy volunteers can take part
Conditions the study is for
SARS-CoV-2
What is being tested?
HIV and Malignant Neoplasms Safety Study for the Treatment of Neoplasms
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
No sites listed yet
Study dates
28 Jan 2025to 4 Feb 2025
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year to 130 years
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • SARS-CoV-2

Who cannot join

None listed.

About this study

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to protect Telomere chromosomes to maintain Acid Deoxyribonucleic (ADN) Molecules.

Read the detailed description

SARS-CoV-2 produced strong pluripotent stem cells and brain cells to change and disappear defective cells in virus variants, Covid-19 disease. Pluripotent stem cells produced strong cells serve as a repair system, replacing damaged cells, defective cells and dead cells.

CHEMISTRY:

SARS-CoV-2 does not use any chemicals, no colors and no additives and no preservatives.

Toxicology:

SARS-CoV-2 product is not adverse effect, non-toxic and no pharmacal toxicology.

SARS-CoV-2 is not placebo drug

Conditions
SARS-CoV-2
Being tested
HIV, Malignant Neoplasms Safety Study for the Treatment of Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HIVDrug

    Also called HIV Safety Study for the Treatment of Anti-AIDS Drug

    Directions: For adults and for Children 1-12 years old. Indication: HIV Ingredient: Organic Rice 93% and Honey 7% Powder (whole) 1g. Masking: None (Open Label) Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours.

    Humidification: <5% Dosage Form:

    Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date

  • Malignant Neoplasms Safety Study for the Treatment of NeoplasmsDrug

    Also called Malignant Neoplasms

    Directions: For adults and for Children 1-12 years old. Indication: Malignant Neoplasms . Ingredient: Organic Rice 92% and Honey 8% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: <5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date.

Study groups in NCT06489860
Study groupRoleWhat they receive
SARS-CoV-2 Safety Study for the Treatment of COVID-19ExperimentalDirections: For adults and for Children 1-12 years old. Indication:SARS-CoV-2 Ingredients: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Humidification: <5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Use within two years from the manufacturing date. Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).
Receives: Drug: HIV; Drug: Malignant Neoplasms Safety Study for the Treatment of Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. SARS-CoV-2

    1. Parameters: Humidification, Unit: %, Result: 4.40, Test Method: ISO 7932: 2004.
    2. Cadmium (Cd), mg/Kg, 0.1, CASE.TN.0018 (Ref. AOAC 999.11).
    3. Hydrargyrum (Hg), mg/Kg, 0.01, CASE.TN.0141 (Ref . EPA Method 7473).
    4. Plumbum (Pb), mg/liter, 0.001, SMEWW3030E 2017: 31258: 2017.
    5. Cadmium (Cd), mg/liter, 0.0001, SMEWW3030E 2017: 31258: 2017. .
    6. Arsen (As), mg/liter, 0.001, SMEWW3030E 2017: 31258: 2017.
    7. Hydrargyrum (Hg), mg/liter, 0.0001, SMEWW3030E 2017: 31258: 2017.
    8. Clostridium perfringents, CFU/g, < 10, ISO 7937:2004.
    9. Coliforms, CFU/g, < 10, ISO 4832:2006 (*).
    10. Escherichia coli, CFU/g, < 10, ISO 7937:2006.
    11. Salmonella, /25g, Not detected, ISO 7937:2007.
    12. Staphylococcus aureus, CFU/g, < 10, ISO 7937:2008.
    13. Total Yeasts molds, CFU/g, < 10, ISO 7937:2009.
    14. Total Aerobic Microbial, CFU/g, 1.0 x 100, ISO 7937:2010.
    15. Vibrio parahaemolyticuc, /25g, Not detected, ISO 7937:2011. .

    Measured: From September to October, 2024

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jul 2024
  2. Study start28 Jan 2025
  3. Primary completion30 Jan 2025 (estimated)
  4. Study completion4 Feb 2025 (estimated)

Why it stopped: My record is not overseen by an IRB, I change the Overall Status to Withdrawn.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
SARS-CoV-2. Directions: For adults and for Children 1-12 years old. Indication: SARS-CoV-2. Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g.
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06489860
Sponsor's protocol ID
DHACoffee
Acronym
SARS-CoV-2
Status last verified
Aug 2025
First submitted
5 Mar 2024
Last updated
4 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: 20 -1 g Packets Net Weight 0.70 oz (20 g) Directions: For adults and for Children 1-12 years old. Indication: Treated the SARS-CoV-2 treatment COVID-19 within 20 days Ingredient: Organic Rice 95% and Honey 5% Powder (whole) 1g. Mix one packet with 6.8 fl oz (200 ml) of hot water (220ºF/100ºC) about three minutes until dissolved. Participants: Use 4 to 5 packets, use one pack each time after two hours. Use within two years from the manufacturing date. Humidification: \<5% Dosage Form: Powder form Dosage Strength: 1.0 G/ 1 Unit, use one pack of 1 g for each time Storage normal conditions in dry, cool and temperature from 15 °C to 32 °C Store in a dry environment (75% humidity).

Publications

  • Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database--update and key issues. N Engl J Med. 2011 Mar 3;364(9):852-60. doi: 10.1056/NEJMsa1012065.

    PubMed 21366476

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing HIV and Malignant Neoplasms Safety Study for the Treatment of Neoplasms in people with SARS-CoV-2, run by DHA Coffee Co., Ltd.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 4 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

SARS-CoV-2 (time frame: From September to October, 2024). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06489860, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in